Moteur de recherche d’entreprises européennes
Financement de l’UE (1 750 000 €) : L’initiative GetReal Hor 01/06/2018 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
L’initiative GetReal
The GetReal Initiative brings together partners from the IMI GetReal project to drive the adoption of tools, methodologies and best practices from IMI GetReal and increase the quality of real-world evidence (RWE) generation in medicines development and regulatory/HTA processes across Europe. We will establish, in Work Package (WP) 1, a Think Tank, a number of Task Forces and a RWE Research Community. The Think Tank will consist of international thought leaders and will discuss, assesses and give recommendations on the opportunities and barriers to the generation, use and acceptability of RWE. They will act as ambassadors for the use of RWE during the project and beyond, enagaging with key stakeholder groups to drive policy debate and facilitate the uptake of the outputs of IMI GetReal and the GetReal Initiative. The GetReal Taskforces will drive the focused development of tangible solutions to the key challenges identified in IMI GetReal and the Think Tank. The initial three task forces will be: (i) Pragmatic Trials (design, operational feasibility and analysis/the GetReal PragMagic tool), (ii) network meta-analysis and benefit risk assessment (incl. the GetReal ADDIS tool) and (iii) Statistical Approaches for enriching RCTs with real-world data. The GetReal Research Community will consist of researchers and organisations active in the field of RWE generation, regulators, HTAs, physicians and patients. The Community will review and comment on any GetReal Initiative guidelines, recommendations or white papers ahead of their finalisation, will have access to all the GetReal tools and outputs, receive regular newsletters and receive invitations to attend stakeholder events. The project will also invest in long term sustainability of the GetReal Initiative and the tools on a not-for-profit basis (WP2). The project is supported by professional experienced consortium management (WP3) and an ethics work package (WP4).
| Academisch Ziekenhuis Groningen | 393 200 € |
| Amgen Ltd. | 0,00 € |
| Astellas Pharma Europe B.V. | 0,00 € |
| Astrazeneca AB | 0,00 € |
| Bayer AG | 0,00 € |
| Eli Lilly and Company Ltd. | 0,00 € |
| Glaxosmithkline Research & Development Ltd. | 0,00 € |
| International Alliance of Patient'Organizations | 90 000 € |
| L.A Sante, Epidemiologie, Evaluation et Recherche L.A.S.E.R. | 210 000 € |
| National Institute for Health and Care Excellence | 220 000 € |
| Sanofi-Aventis Recherche & Developpement | 0,00 € |
| Takeda Development Centre Europe Ltd. | 0,00 € |
| Takeda Pharmaceuticals International AG | 0,00 € |
| UCB Biopharma | 0,00 € |
| Universitair Medisch Centrum Utrecht | 525 000 € |
| Vital Transformation | 201 800 € |
| Zorginstituut Nederland | 110 000 € |
https://cordis.europa.eu/project/id/807012
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.